Minimally-invasive Treatment Option
PULMONX NAMES INDUSTRY VETERAN TO BOARD OF DIRECTORS
Pulmonx Names Industry Veteran to Board of Directors Redwood City,…
PULMONX ANNOUNCES THAT UNITEDHEALTHCARE, THE LARGEST COMMERCIAL INSURER IN THE UNITED STATES, HAS LIFTED COVERAGE RESTRICTIONS ON THE ZEPHYR VALVE, A MINIMALLY-INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)
Both UnitedHealthcare® and EmblemHealth recently announced positive coverage…
THE NEW 2020 REPORT FROM THE GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) GIVES HIGHEST EVIDENCE RATING TO ENDOBRONCHIAL VALVES, INCLUDING THE ZEPHYR VALVE, FOR TREATMENT OF EMPHYSEMA / COPD
GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr…